updated 9/29/2009 12:34:37 PM ET 2009-09-29T16:34:37

The Food and Drug Administration has delayed a decision on GlaxoSmithKline's vaccine for cervical cancer, according to the British drugmaker.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The FDA was scheduled to announce its ruling Tuesday on whether to approve Cervarix, but a Glaxo spokeswoman said the review will continue.

The announcement came one day after British health officials reported a 14-year-old girl died a few hours after receiving the vaccine.

Britain's National Health Service began offering Cervarix to teenage girls last year, and more than 1.4 million doses of the vaccine have been given out under the program.

Glaxo spokeswoman Sarah Alspach said the death did not influence the FDA's decision to extend its review.

"The FDA has not indicated the extended review is related to any safety concern," Alspach said in a statement.

An FDA spokeswoman said the agency does not comment on pending product reviews.

Panel recommended approval of Cervarix
Earlier this month, an outside panel of health experts voted that Cervarix appears safe and effective for girls and women ages 10 to 25. The FDA is not required to follow the group's advice, though it usually does.

Cervarix already is approved in nearly 100 other countries, but has been delayed in the U.S. since 2007, when the FDA said it needed additional data. The vaccine blocks the two main viruses that cause most cases of cervical cancer.

An approval from FDA would allow London-based Glaxo to compete against Merck's blockbuster vaccine Gardasil, which has been on the market here since 2006.

The human papilloma virus, or HPV, infects about 6 million people in the U.S. each year, and is spread mainly through sexual contact. It usually causes no symptoms and goes away within two years, although rare cases can develop into warts and cancer in both men and women.

Last year, nearly 4,000 women died of cervical cancer in the U.S., fewer than 1 percent of all deaths from cancer.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments